H1N1 influenza virus-like particles: Physical degradation pathways and identification of stabilizers

Journal of Pharmaceutical Sciences

Volumn 100, Issue 2, 2011, Pages 634-645

  Kissmann, Julian ^a   Joshi, Sangeeta B ^a   Haynes, Joel R ^b   Dokken, Leslie ^b   Richardson, Charles ^b   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b LigoCyte Pharmaceuticals Inc   (United States)

Author keywords

Bilayer; Circular dichroism; Excipients; Fluorescence spectroscopy; Formulation; Light scattering (dynamic); Light scattering (static); Physical characterization; Physical stability; Vaccines

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2 HYDROXYPROPYL GAMMA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; ARGININE; ASCORBIC ACID; ASPARTIC ACID; DIETHANOLAMINE; EXCIPIENT; GAMMA CYCLODEXTRIN DERIVATIVE; GELATIN; GLUCOSE; GLYCEROL; GLYCINE; GUANIDINE; HISTIDINE; HN PROTEIN; HUMAN ALBUMIN; LACTIC ACID; LACTOSE; LYSINE; MALIC ACID; MANNITOL; POLIDOCANOL; POLOXAMER; POLYSORBATE 20; POLYSORBATE 80; PROLINE; SORBITOL; SUCROSE; TREHALOSE; UNCLASSIFIED DRUG;

ARTICLE; CIRCULAR DICHROISM; DRUG DEGRADATION; FLUORESCENCE; INFLUENZA VIRUS A H1N1; LIGHT SCATTERING; PH; PHASE TRANSITION; POLARIZATION; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; TEMPERATURE; VIRUS ENVELOPE; VIRUS LIKE AGENT;

EID: 78650581772     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22304     Document Type: Article

References (35)

1. Plotkin SA, Orenstein WA. 2004. Vaccines. 4th ed. Philadelphia: Saunders, pp 1662.
2. World Health Organization. 2005. Influenza vaccines. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations [Wkly Epidemiol Rec/Health Sect Secretariat League Nations] 80(33):279-287.
3. Hay AJ, Gregory V, Douglas AR, Lin YP. 2001. The evolution of human influenza viruses. Phil Trans R Soc Lond 356(1416):1861-1870.
4. Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, Richardson C. 2009. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27(4):530-541.
5. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM. 2008. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1):e1501.
6. Matassov D, Cupo A, Galarza JM. 2007. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol 20(3):441-452.
7. Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA 2007. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21):4283-4290.
8. Quan FS, Huang C, Compans RW, Kang SM. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81(7):3514-3524.
9. Peek LJ, Brey RN, Middaugh CR. 2007. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J Pharm Sci 96(1):44-60.
10. Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ. 2006. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 95(1):80-96.
11. Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR. 2008. Preformulation studies of Clostridium difficile toxoids A and B. J Pharm Sci 97(10):4194-4207.
12. Kissmann J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedvick TS, Middaugh CR. 2008. Physical stabilization of Norwalk virus-like particles. J Pharm Sci 97(10):4208-4218.
13. Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE, Federspiel MJ, Joshi SB, Middaugh CR. 2008. Stabilization of measles virus for vaccine formulation. Hum Vacc 4(5):350-359.
14. Ausar SF, Espina M, Brock J, Thyagarayapuran N, Repetto R, Khandke L, Middaugh CR. 2007. High-throughput screening of stabilizers for respiratory syncytial virus: Identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum Vacc 3(3):94-103.
15. Lakowicz JR. 1999. Principles of fluorescence spectroscopy. 2nd ed. New York: Kluwer Academic/Plenum, pp 698.
16. Parasassi T, De Stasio G, Ravagnan G, Rusch RM, Gratton E. 1991. Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of laurdan fluorescence. Biophys J 60(1):179-189.
17. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 92(9):1805-1820.
18. Fan H, Ralston J, Dibiase M, Faulkner E, Middaugh CR. 2005. Solution behavior of IFN-beta-1a: An empirical phase diagram based approach. J Pharm Sci 94(9):1893-1911.
19. Borges N, Ramos A, Raven ND, Sharp RJ, Santos H. 2002. Comparative study of the thermostabilizing properties of mannosylglycerate and other compatible solutes on model enzymes. Extremophiles 6(3):209-216.
20. Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR. 2005. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm 2(6):491-499.
21. White JM. 1992. Membrane fusion. Science 258(5084):917-924.
22. White JM, Wilson IA. 1987. Anti-peptide antibodies detect steps in a protein conformational change: Low-pH activation of the influenza virus hemagglutinin. J Cell Biol 105(6, pt 2):2887-2896.
23. Wiley DC, Skehel JJ. 1987. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 56:365-394.
24. Kemble GW, Danieli T, White JM. 1994. Lipid-anchored influenza hemagglutinin promotes hemifusion, not complete fusion. Cell 76(2):383-391.
25. Colman PM. 1994. Influenza virus neuraminidase: Structure, antibodies, and inhibitors. Protein Sci 3(10):1687-1696.
26. Flanagan MT, Skehel JJ. 1977. The conformation of influenza virus haemagglutinin. FEBS Lett 80(1):57-60.
27. Kelly BN, Howard BR, Wang H, Robinson H, Sundquist WI, Hill CP. 2006. Implications for viral capsid assembly from crystal structures of HIV-1 Gag(1-278) and CA(N)(133-278). Biochemistry 45(38):11257-11266.
28. Mortuza GB, Dodding MP, Goldstone DC, Haire LF, Stoye JP, Taylor IA. 2008. Structure of B-MLV capsid amino-terminal domain reveals key features of viral tropism, gag assembly and core formation. J Mol Biol 376(5):1493-1508.
29. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325-1336.
30. Lee JC, Timasheff SN. 1981. The stabilization of proteins by sucrose. J Biol Chem 256(14):7193-7201.
31. Shimizu S, Smith DJ. 2004. Preferential hydration and the exclusion of cosolvents from protein surfaces. J Chem Phys 121(2):1148-1154.
32. Uedaira H, Uedaira H. 2001. Role of hydration of polyhydroxy compounds in biological systems. Cell Mol Biol 47(5):823-829.
33. Luzardo MC, Amalfa F, Nunez AM, Diaz S, Biondi De Lopez AC, Disalvo EA. 2000. Effect of trehalose and sucrose on the hydration and dipole potential of lipid bilayers. Biophys J 78(5):2452-2458.
34. Ricker JV, Tsvetkova NM, Wolkers WF, Leidy C, Tablin F, Longo M, Crowe JH. 2003. Trehalose maintains phase separation in an air-dried binary lipid mixture. Biophys J 84(5):3045-3051.
35. Rudolph AS, Crowe JH, Crowe LM. 1986. Effects of three stabilizing agents-proline, betaine, and trehalose-on membrane phospholipids. Arch Biochem Biophys 245(1):134-143.